Literature DB >> 21525842

Monitoring tumor metastases and osteolytic lesions with bioluminescence and micro CT imaging.

Ed Lim1, Kshitij Modi, Anna Christensen, Jeff Meganck, Stephen Oldfield, Ning Zhang.   

Abstract

Following intracardiac delivery of MDA-MB-231-luc-D3H2LN cells to Nu/Nu mice, systemic metastases developed in the injected animals. Bioluminescence imaging using IVIS Spectrum was employed to monitor the distribution and development of the tumor cells following the delivery procedure including DLIT reconstruction to measure the tumor signal and its location. Development of metastatic lesions to the bone tissues triggers osteolytic activity and lesions to tibia and femur were evaluated longitudinally using micro CT. Imaging was performed using a Quantum FX micro CT system with fast imaging and low X-ray dose. The low radiation dose allows multiple imaging sessions to be performed with a cumulative X-ray dosage far below LD50. A mouse imaging shuttle device was used to sequentially image the mice with both IVIS Spectrum and Quantum FX achieving accurate animal positioning in both the bioluminescence and CT images. The optical and CT data sets were co-registered in 3-dimentions using the Living Image 4.1 software. This multi-mode approach allows close monitoring of tumor growth and development simultaneously with osteolytic activity.

Entities:  

Mesh:

Year:  2011        PMID: 21525842      PMCID: PMC3169249          DOI: 10.3791/2775

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  5 in total

1.  Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors.

Authors:  Andy J Minn; Yibin Kang; Inna Serganova; Gaorav P Gupta; Dilip D Giri; Mikhail Doubrovin; Vladimir Ponomarev; William L Gerald; Ronald Blasberg; Joan Massagué
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

Review 2.  Whole-body optical imaging in animal models to assess cancer development and progression.

Authors:  Eric L Kaijzel; Gabri van der Pluijm; Clemens W G M Löwik
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

3.  Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.

Authors:  Agatha Labrinidis; Shelley Hay; Vasilios Liapis; Vladimir Ponomarev; David M Findlay; Andreas Evdokiou
Journal:  Clin Cancer Res       Date:  2009-04-28       Impact factor: 12.531

4.  Breast cancer metastasis to bone: evaluation of bioluminescent imaging and microSPECT/CT for detecting bone metastasis in immunodeficient mice.

Authors:  S Cowey; A A Szafran; J Kappes; K R Zinn; G P Siegal; R A Desmond; H Kim; L Evans; R W Hardy
Journal:  Clin Exp Metastasis       Date:  2007-05-31       Impact factor: 5.150

5.  Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice.

Authors:  Darlene E Jenkins; Yvette S Hornig; Yoko Oei; Joan Dusich; Tony Purchio
Journal:  Breast Cancer Res       Date:  2005-04-08       Impact factor: 6.466

  5 in total
  10 in total

1.  CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation.

Authors:  Yuan Liu; Elianna B Amin; Marty W Mayo; Neel P Chudgar; Peter R Bucciarelli; Kyuichi Kadota; Prasad S Adusumilli; David R Jones
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

2.  Bioluminescent orthotopic model of pancreatic cancer progression.

Authors:  Ming G Chai; Corina Kim-Fuchs; Eliane Angst; Erica K Sloan
Journal:  J Vis Exp       Date:  2013-06-28       Impact factor: 1.355

3.  Murine models of breast cancer bone metastasis.

Authors:  Laura E Wright; Penelope D Ottewell; Nadia Rucci; Olivier Peyruchaud; Gabriel M Pagnotti; Antonella Chiechi; Jeroen T Buijs; Julie A Sterling
Journal:  Bonekey Rep       Date:  2016-05-11

4.  Autocrine inhibition of the c-fms proto-oncogene reduces breast cancer bone metastasis assessed with in vivo dual-modality imaging.

Authors:  Justin J Jeffery; Katie Lux; John S Vogel; Wynetta D Herrera; Stephen Greco; Ho-Hyung Woo; Nisreen AbuShahin; Mark D Pagel; Setsuko K Chambers
Journal:  Exp Biol Med (Maywood)       Date:  2014-03-05

5.  Opening up the optical imaging window using nano-luciferin.

Authors:  Apurva R Patel; Ed Lim; Kevin P Francis; Mandip Singh
Journal:  Pharm Res       Date:  2014-05-16       Impact factor: 4.200

6.  Improving In Vivo High-Resolution CT Imaging of the Tumour Vasculature in Xenograft Mouse Models through Reduction of Motion and Bone-Streak Artefacts.

Authors:  Veerle Kersemans; Pavitra Kannan; John S Beech; Russell Bates; Benjamin Irving; Stuart Gilchrist; Philip D Allen; James Thompson; Paul Kinchesh; Christophe Casteleyn; Julia Schnabel; Mike Partridge; Ruth J Muschel; Sean C Smart
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

7.  Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer.

Authors:  A M Poff; C Ari; P Arnold; T N Seyfried; D P D'Agostino
Journal:  Int J Cancer       Date:  2014-05-14       Impact factor: 7.396

8.  Contrast-enhanced micro-CT imaging in murine carotid arteries: a new protocol for computing wall shear stress.

Authors:  Ruoyu Xing; David De Wilde; Gayle McCann; Yanto Ridwan; Jelle T C Schrauwen; Anton F W van der Steen; Frank J H Gijsen; Kim Van der Heiden
Journal:  Biomed Eng Online       Date:  2016-12-28       Impact factor: 2.819

9.  Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents.

Authors:  Xiao-xi Lv; Xiao-xing Wang; Ke Li; Zi-yan Wang; Zhe Li; Qi Lv; Xiao-ming Fu; Zhuo-wei Hu
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

10.  Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer.

Authors:  Cian M McCrudden; John W McBride; Joanne McCaffrey; Emma M McErlean; Nicholas J Dunne; Vicky L Kett; Jonathan A Coulter; Tracy Robson; Helen O McCarthy
Journal:  Cancer Nanotechnol       Date:  2018-06-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.